“活药物”靶向晚期肾肿瘤中的 CD70。
'Living drugs' target CD70 in advanced renal tumors.
机构信息
Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.
Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.
出版信息
Trends Pharmacol Sci. 2024 Sep;45(9):757-759. doi: 10.1016/j.tips.2024.07.002. Epub 2024 Jul 29.
PMID:39079777
Abstract
Cellular therapies against solid tumors face three major barriers: low persistence, insufficient specificity, and high costs. In a recent study, Pal et al. tackle these challenges in kidney cancer by using novel, 'persistence-tuned' allogeneic chimeric antigen receptor (CAR) T cells directed against a stable antigen.
摘要
针对实体肿瘤的细胞疗法面临三大障碍
持久性低、特异性不足和高成本。在最近的一项研究中，Pal 等人通过使用针对稳定抗原的新型、“持久性调整”同种异体嵌合抗原受体 (CAR) T 细胞来应对肾癌中的这些挑战。
Zotero 插件